I think it depends on the underlying mutation? Is this high yield?
Seems like a good change, but we should mention osimertinib in another card regarding erlotinib and EGFR inhibition because it isn’t mentioned anywhere else in the deck. Just for context, FA23 does not list osimertinib in their list of EGFR small molecule inhibitors (pg447)